Question

What is Keytruda's (Pembrolizumab) reimbursement methodology?

Answer 1

Keytruda's (Pembrolizumab) would be reimbursed as monotherapy

-- The treatment in adults for the locally advanced or metastatic NSCLC where in the express tumours PD-L1 with a ≥1% tumour proportion score and have at least received one prior chemotherapy regimen. The patients with ALK or EGFR positive mutations on tumour must have received therapy targeted before receiving Keytruda

-- The first-line treatment in adults on the metastatic non-small cell lung carcinoma where in the express tumours PD-L1 with a ≥50% proportion score for tumour with no ALK or EGFR tumour positive mutations

-- The treatment of patients who are adults and with refractory or relapsed classical Hodgkin lymphoma who have not passed the brentuximab vedotin and autologous stem cell transplant, or those who are ineligible for transplant and have failed BV

-- The treatment of advanced locally or metastatic urothelia